Analyst Reco. Revance Therapeutics, Inc.

Equities

RVNC

US7613301099

Market Closed - Nasdaq Other stock markets 21:30:01 06/05/2024 BST			5-day change	1st Jan Change
4.1 ^USD	+3.80%		+11.11%	-53.36%

05-04	Certain Restricted Stock Units of Revance Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 4-MAY-2024.	CI
05-04	Certain Common Stock of Revance Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 4-MAY-2024.	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Goldman Sachs Adjusts Price Target on Revance Therapeutics to $9 From $8, Maintains Neutral Rating	03-01	MT
Needham Cuts Price Target on Revance Therapeutics to $18 From $20, Maintains Buy Rating	02-29	MT
Piper Sandler Cuts Price Target on Revance Therapeutics to $20 From $42, Maintains Overweight Rating	02-29	MT
Mizuho Securities Downgrades Revance Therapeutics to Neutral From Buy, Lowers Price Target to $9 From $16	01-29	MT
Needham Cuts Price Target on Revance Therapeutics to $20 From $25, Maintains Buy Rating	01-09	MT
Goldman Sachs Downgrades Revance Therapeutics to Neutral From Buy, Cuts Price Target to $8 From $30	01-09	MT
Mizuho Adjusts Revance Therapeutics' Price Target to $16 From $35, Maintains Buy Rating	11-22	MT
Piper Sandler Adjusts Revance Therapeutics' Price Target to $42 From $44, Maintains Overweight Rating	11-09	MT
Needham Adjusts Revance Therapeutics Price Target to $25 From $35, Maintains Buy Rating	11-09	MT
HC Wainwright Adjusts Revance Therapeutics' Price Target to $15 From $41, Keeps Buy Rating	11-06	MT
Barclays Adjusts Revance Therapeutics' Price Target to $35 From $40, Maintains Overweight Rating	23/10/23	MT
Morgan Stanley Lowers Price Target on Revance Therapeutics to $12 From $25, Maintains Equalweight Rating	11/10/23	MT
Goldman Sachs Adjusts Revance Therapeutics' Price Target to $33 From $38, Keeps Buy Rating	21/09/23	MT
Piper Sandler Adjusts Price Target on Revance Therapeutics to $44 From $50, Maintains Overweight Rating	20/09/23	MT
Needham Adjusts Revance Therapeutics Price Target to $35 From $40, Maintains Buy Rating	20/09/23	MT
BNP Paribas Exane Upgrades Revance Therapeutics to Neutral From Underperform, Price Target is $20	16/08/23	MT
Morgan Stanley Adjusts Price Target on Revance Therapeutics to $25 From $26, Maintains Equal-Weight Rating	09/08/23	MT
Needham Adjusts Price Target on Revance Therapeutics to $40 From $44, Maintains Buy Rating	09/08/23	MT
HC Wainwright Adjusts Price Target on Revance Therapeutics to $41 From $48, Maintains Buy Rating	09/08/23	MT
Mizuho Securities Adjusts Revance Therapeutics Price Target to $35 From $33, Maintains Buy Rating	07/06/23	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Revance Therapeutics, Inc.

Equities

RVNC

US7613301099

Analyst Reco.

Filters